9 Sept - Asia Bio Day 1Tuesday, 9 September 2025 - SGT / Singapore

APAC is no longer an emerging player; it’s a rising force in the global biotech arena. But how does the region move from potential to leadership? This keynote brings together top investors, CEOs, and dealmakers to explore how biotech companies in Asia can scale, partner, and lead on the world stage. From cross-border deals to breakthrough science, this discussion outlines the strategic moves shaping APAC’s global trajectory.

• What’s driving the most exciting biotech deals across APAC today, and what’s next?
• How are companies positioning themselves to attract global partners, capital, and talent?
• Understanding the key enablers for taking science from local discovery to global impact?
• In what way can the region’s unique strengths be leveraged to compete and lead in innovation and commercialization?

Session Themes: Strategy / Dealmaking / Investment / Collaboration

APAC’s biotech landscape isn’t driven by a single dominant hub, but by a mosaic of strengths across the region. From cutting-edge science, and robust clinical infrastructure to leading manufacturing capabilities and financial depth, each APAC market offers unique advantages. This session explores how deeper cross-border collaboration, across Asia and between continents, can unlock innovation, streamline development, and enhance Asia’s role in the global biotech ecosystem.

• How can regional integration accelerate innovation and make Asia more globally competitive?
• What are the most effective ways to align R&D, clinical development, and commercialization across Asia and between continents?
• How can companies and investors strategically tap into country-specific advantages to scale faster and smarter?
• What are some of the strategies that biotech companies can deploy to navigate and even anticipate regulatory and political headwinds in an increasingly fragmented global landscape?

Session Themes: Collaboration / Innovation / Market Access

APAC's biotech ecosystem is rapidly emerging as a powerhouse for novel therapeutic platforms, including mRNA, gene editing, and cell-based therapies. However, advancing these complex modalities requires overcoming unique investment, infrastructure, and regulatory challenges. This session will focus on how investors and innovators are collaborating to unlock early-stage value and accelerate the journey from platform innovation to patient impact.

• Where is APAC seeing the strongest investor interest in advanced therapeutic platforms?
• How are innovators addressing infrastructure and regulatory hurdles specific to modalities like mRNA and gene therapy?
• In a landscape often lacking mature comparator data, how can early-stage platforms demonstrate differentiation and long-term value, while addressing scalability and affordability for broader regional impact?

Session Themes: Investment / Infrastructure / Early-Stage Innovation / Advanced Therapeutic

The fusion of artificial intelligence with biotech is opening new frontiers in how we discover, develop, and deliver medicine. From accelerating target identification to enabling truly personalized therapies, AI is transforming both the pace and precision of innovation. This fireside chat explores how AI is pushing the boundaries of drug discovery, the path to scalable personalized medicine, and the collaborations driving this revolution forward.

• How is AI evolving from predictive tool to active partner in drug discovery and development?
• What data and infrastructure barriers are hindering progress, and how can they be overcome?
• How can AI drive meaningful advances in precision medicine, and what is needed to integrate these innovations into mainstream clinical practice?
• Where are biotechs and pharma successfully integrating AI into R&D, where are the friction points, and how are they addressing the ethical implications of AI-driven science?

Session Themes: AI / Drug Discovery / Precision Medicine / Innovation / Collaboration

In biotech, a great idea is just the beginning. What truly captures investor attention? In this candid fireside chat, leading biotech investors and dealmakers reveal what separates a compelling pitch from a forgettable one and why leadership, clarity, and strategic storytelling rival the science in importance. Expect honest insights, hard truths, and practical advice on what makes investors commit or walk away.

• What instantly signals to an investor that a biotech CEO is worth backing?
• How do investors evaluate the team’s ability to deliver beyond the science?
• What’s the biggest pitfall biotech founders make when pitching for funding?
• How can CEOs differentiate their company to stand out in a crowded, cautious market?

Session Themes: Investment / Fundraising / Strategy / Startups / Dealmaking

Closing day one with an electrifying live pitch competition featuring some of the most innovative biotech startups today. A select group of rising companies will take the stage to present their breakthrough ideas to the Asia Bio Partnering Forum audience and a panel of esteemed judges.

The winner will receive a complimentary ticket to a future EBD Group event, along with exciting prizes to be announced! Don’t miss this opportunity to witness the next wave of biotech innovation in action.

Pitching In Order:

Drug Delivery: ArrayPatch ltd

Technologies and Tools: ChemT Biotechnology

Medical Devices: Keyron Ltd

Vaccines: Katalyze AI

Autoimmune/Inflammation: Pamplona Therapeutics

Cell and Gene Therapies: Transit Therapeutics